

## Mometasone Furoate nasal spray

Under development

Active ingredient	Mometasone furoate
Strength	50 µg/dose
Therapeutic indication	Allergic rhinitis
Reference (originator) product	Nasonex 50 µg/dose, nasal spray suspension
Pharmaceutical form	Nasal spray suspension
Pack Size	60 doses 120 doses 140 doses
Packaging	Glass bottle HDPE bottle
Finished product manufacturer	Basic Pharma Manufacturing – The Netherlands
Biostudy	No, an in-vitro brand comparison study is performed
Clinical trial	No
Regulatory status	Dossier format: e-CTD DCP application with NL as RMS. CMS countries: tbd.
Shelf-life	3 year (expected)
Batch size	800 kg

For any other information please contact:

Business Development

[bd@basicpharma.nl](mailto:bd@basicpharma.nl)

Burgemeester Lemmensstraat 352

6163 JT Geleen

Netherlands

+31(0)88 255 40 10

basicpharma.nl